Tyra Biosciences (TYRA) Enterprise Value (2020 - 2026)

Tyra Biosciences has reported Enterprise Value for 7 years, with the latest figure at -$85.0 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 15.65% year-over-year to -$85.0 million; the trailing twelve-month figure through Mar 2026 stood at -$85.0 million (up 15.65% YoY), and the FY2025 full-year result was -$77.4 million, up 15.85% from the prior year.
• Enterprise Value for Q1 2026 stood at -$85.0 million, down from -$77.4 million in the prior quarter.
• The five-year high for Enterprise Value was -$58.0 million in Q4 2023, with the low at -$292.5 million in Q1 2022.
• Historically, Enterprise Value has averaged -$164.9 million across 5 years, with a median of -$103.9 million in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value slumped 107.98% — and 2023, when it surged 76.91%.
• Tyra Biosciences' Enterprise Value stood at -$251.2 million in 2022, then surged by 76.91% to -$58.0 million in 2023, then tumbled by 58.55% to -$92.0 million in 2024, then increased by 15.85% to -$77.4 million in 2025, then declined by 9.78% to -$85.0 million in 2026.
• The last three Enterprise Value figures came in at -$85.0 million (Q1 2026), -$77.4 million (Q4 2025), and -$62.0 million (Q3 2025), per Business Quant data.